clinical trial · NCT06942156
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
Heart TransplantEverolimusMycophenolate mofetil Tablet/Capsule
brief summary
The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.
started
Aug 14, 2025
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
Apr 24, 2025
detailed description
This study is a prospective, multicenter, open-label, randomized, comparative, phase 4 trial to optimize immunosuppressive therapy using everolimus and low-dose calcineurin inhibitors in heart transplant patients in Korea.
official title
A Prospective, Multicenter, Open-Label, Randomized, Comparative, Phase 4 Trial to Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol